Table 2.

Time intervals between infusions, analyzed as function of the macroarea of origin

	North (N = 231)	Center (N = 159)	South (N = 209)	Total (N = 599)
OCR-ID-PRE-LOCK (∆1), wk—mean (SD)	27.65 (1.65)	28.58 (3.59)	28.20 (2.86)	28.09 (2.73)
∆1 subgroups, N
∆1 ≥ 22 and < 26	18 (7.8%)	27 (17.0%)	34 (16.3%)	79 (13.2%)
∆1 ≥ 26 and < 30	198 (85.7%)	96 (60.4%)	139 (66.5%)	433 (72.3%)
∆1 ≥ 30	15 (6.5%)	36 (22.6%)	36 (17.2%)	87 (14.5%)
OCR-ID-LOCK-PRE-LOCK (∆2), week—mean (SD)	32.32 (6.19)	30.07 (4.72)	29.75 (4.71)	30.83 (5.45)
∆2 subgroups, N
∆2 ≥ 22 and < 26	13 (5.6%)	23 (14.5%)	33 (15.8%)	69 (11.5%)
∆2 ≥ 26 and < 30	81 (35.1%)	62 (39.0%)	88 (42.1%)	231 (38.6%)
∆2 ≥  = 30	137 (59.3%)	74 (46.5%)	88 (42.1%)	299 (49.9%)

N number; wk weeks; SD standard deviation; OCR Ocrelizumab; PRE-LOCK OCR cycle occurred between August and December 2019; ID-PRE-LOCK time interval, in weeks, between all the infusions prior to the pre-lock cycle; LOCK OCR cycle following pre-lock cycle, between February and June 2020; ID-LOCK-PRE-LOCK time interval, in weeks, between the pre-lock and the lock cycle